Abstract
In February 2008, rilonacept (Arcalyst; Regeneron), an interleukin 1 blocker, was approved by the US FDA for the treatment of a group of rare autoinflammatory diseases known as cryopyrin-associated periodic syndromes.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Identification and validation of uterine stimulant methylergometrine as a potential inhibitor of caspase-1 activation
Apoptosis Open Access 28 July 2017
-
Modulation of Inflammasome Activity for the Treatment of Auto-inflammatory Disorders
Journal of Clinical Immunology Open Access 01 April 2010
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Shinkai, K. et al. Cryopyrin-associated periodic syndromes and autoinflammation. Clin. Exp. Dermatol. 33, 1–9 (2008).
Drenth, J. P. H. & van der Meer, J. W. M. The inflammasome — a linebacker of innate defense. N. Engl. J. Med. 355, 730–732 (2006).
Hoffman, H. M. et al. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle–Wells syndrome. Nature Genet. 29, 301–305 (2001).
Agostini, L. et al. NALP3 forms an IL-1β-processing inflammasome with increased activity in Muckle–Wells autoinflammatory disorder. Immunity 20, 319–325 (2004).
Hawkins, P. N. et al. Interleukin-1-receptor antagonist in the Muckle–Wells syndrome. N. Engl. J. Med. 348, 2583–2584 (2003).
Hoffman, H. M. et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 364, 1779–1785 (2004).
Economides, A. N. et al. Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nature Med. 9, 47–52 (2003)
Food and Drug Administration. FDA labelling information [online], (2008).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
Hal M. Hoffmann is a consultant for Regeneron.
Rights and permissions
About this article
Cite this article
Hoffman, H., Yasothan, U. & Kirkpatrick, P. Rilonacept. Nat Rev Drug Discov 7, 385–386 (2008). https://doi.org/10.1038/nrd2579
Issue Date:
DOI: https://doi.org/10.1038/nrd2579
This article is cited by
-
Identification and validation of uterine stimulant methylergometrine as a potential inhibitor of caspase-1 activation
Apoptosis (2017)
-
Modulation of Inflammasome Activity for the Treatment of Auto-inflammatory Disorders
Journal of Clinical Immunology (2010)
-
IL-1β-targeted antibody approved for rare autoinflammatory disorders
Nature Reviews Drug Discovery (2009)